Vicentini M, et al. - Researchers examined all incident cases occurring in 50- to 71-year-olds (from 2000 to 2008) residing in areas with a fecal immunochemical test (FIT)-screening program in order to evaluate the impact of FIT screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs unscreened. This study included 11,663 cancers: 5,965 in not-invited and 5,698 in invited patients, 3425 of whom attendees. Compared with not-invited, invited patients displayed relative risk ratio of 2.04 for stage I and 0.77 for stage IV. Stronger differences were noted comparing attendees vs non-attendees. Compared with non-invited, interval cancers were more frequently stage I; however, no difference for stage IV was noted. Findings thus suggested FIT screening as effective in reducing the incidence of metastatic cancers by about 70% after the first round.